EDITOR'S CHOICE NEWS Builder offers reward after van stolen Government pledge on cancer-drugs lottery OXFORD UNITED FOOTBALL: U's players set for hard slog EATING OUT The Black Horse, Checkendon CRICKET CRICKET: Challow close in on leaders CRICKET: Shrivenham miss out on final place NEWS Update: UK 'ill prepared' for floods VOTE Is it right that cancer patients should have to pay for their own treatment? Yes No GET OUR NEWS BY E-MAIL Just register

Most read Comments 1 Drugs dealer jailed at last 2 Motorist freed from smash wreckage 3 Update: Jams form as Game Fair opens 4 Development gets go-ahead 5 Former mayoress fears men's return 6 Meadows chosen to fly the flag 7 Boy wins £5.5m for NHS blunder 8 Heart problem clue to crash 9 Head and deputy head bid farewell in villages 10 Death-crash victim named Today | 7 Days 1 Baldry and Howell go head-to-head with Flint 2 Miss Oxford bows out of competition 3 Ex-teacher: Pills made me a pervert 4 Showdown meeting over housing plan 5 Campaigners claim lake victory 6 New TV news programme launched 7 Parking problems 8 Drugs dealer jailed at last 9 FLOOD ONE YEAR ON: 'Never say never again' 10 Radio audience dips

Taking the chair: Alan Kingsman

The board of a pioneering biotech firm is undergoing a major shake-up with its co-founder retiring from her senior role.

Professor Susan Kingsman will step down from her position as chief scientific officer and executive director of Oxford Biomedica, while her partner, Professor Alan Kingsman, will move from chief executive to chairman.

Current non-executive director Dr Peter Johnson will retire with Dr Mike McDonald moving from chief medical officer to chief executive.

Alan Kingsman said: "I look forward to working with Mike, as we take Oxford BioMedica to its next stage of corporate and commercial success."

Mr Johnson added: "It has been a great pleasure being part of the team at Oxford BioMedica that has seen the company progress from an early-stage research organisation to become a leading UK biopharmaceutical company."

Oxford Biomedica, based at the Oxford Science Park, is set to launch its first cancer drug, TroVax, for the treatment of advanced kidney cancer in about 18 months time.

The product has also been successfully tested on bowel and prostate cancer sufferers.

Dr Stuart Naylor, currently senior vice president, research and development, will take Susan Kingsman's place on the board. She will continue to work for the company she helped set up in 1995 as a senior scientific consultant.

Nick Rodgers, the company's senior independent director, will step up to become deputy chairman.

The changes will take effect on July 1.

11:43am Tuesday 15th April 2008

Print

Email this